CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Pioglitazone for Type 2 Diabetes Mellitus and Pre-Diabetes: A Review of Safety

Last updated: June 22, 2020
Project Number: RC1285-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical evidence regarding the safety of pioglitazone for patients with type 2 diabetes or pre-diabetes?

Key Message

Five relevant systematic reviews (four with meta-analysis and one with network meta-analysis), two randomized controlled trials, and six non-randomized studies were identified regarding the safety of pioglitazone for patients with pre-diabetes or type 2 diabetes.In patients with pre-diabetes, evidence from one non-randomized study suggested that pioglitazone was associated with an increased likelihood of weight gain and edema when compared to placebo, while studies evaluating other safety outcomes generally found no significant differences between pioglitazone and comparators. Results in patients with type 2 diabetes were mixed, though there were often no significant differences from systematic reviews regarding several safety outcomes when comparing pioglitazone to other treatments for type 2 diabetes. However, the body of evidence was largely of low to moderate quality. As such, there remains some uncertainty around the overall safety profile of pioglitazone.The limitations of the included studies (e.g., heterogeneity of the literature, and lack of blinding to treatment), should be considered when interpreting the results.